Clinical Trial Update: Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial of entinostat with anastrozole in postmenopausal women with resectable triple-negative breast cancer (TNBC) was terminated; results posted in 2022…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Anastrozole (Anastrozole)
• Entinostat (entinostat)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2022-05-03